Catalyst

Slingshot members are tracking this event:

Phase 3 VITAL study results for NEOD001 in newly diagnosed patients with AL Amyloidosis in cardiac dysfunction. - Discontinued

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PRTA

100%

Additional Information

Management Comment We expect to fully enroll this study with approximately 230 patients in the second quarter of this year. (2016)

Study is 9 months long from clinical trials.gov
https://clinicaltria...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 23, 2018
Occurred Source:
Related Keywords Neod001, Vital Study, Al Amyloidosis, Nt-probmp, Discontinued